They also suggest that PAR signaling can both augment and oppose those responses. Such a paradoxical role for the PARs should perhaps not be surprising, as it mirrors the paradox of thrombin ...

Four years ago, protein drug developer Zymogenetics in Seattle began developing a recombinant version of the blood-clotting protein thrombin. On 17 January, it received US marketing approval for ...